About Ceptaris Therapeutics
Ceptaris Therapeutics is a company based in Malvern (United States) founded in 2002 was acquired by Actelion in July 2013. Ceptaris Therapeutics has raised $49.04 million across 10 funding rounds from investors including SVB, Actelion and HHS.
- Headquarter Malvern, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ceptaris Therapeutics
Ceptaris Therapeutics has successfully raised a total of $49.04M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $10 million completed in May 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ceptaris Therapeutics
Ceptaris Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Actelion and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector investments are managed through private equity strategies.
|
Locked | Locked | Locked | |
|
A healthcare-focused investment firm supporting innovative company growth.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Ceptaris Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ceptaris Therapeutics
Investment portfolio details for Ceptaris Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ceptaris Therapeutics
Detailed financials for Ceptaris Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ceptaris Therapeutics Comparisons
Peer comparison for Ceptaris Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ceptaris Therapeutics
Detailed competitors of Ceptaris Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ceptaris Therapeutics
Complete news archive for Ceptaris Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ceptaris Therapeutics
Ceptaris Therapeutics was founded in 2002.
Ceptaris Therapeutics is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania, United States.
Ceptaris Therapeutics is a funded company, having raised a total of $49.04M across 10 funding rounds to date.
Ceptaris Therapeutics was founded in 2002 and headquartered in Malvern, United States, as a clinical-stage biopharmaceutical company. Focus was placed on developing Mechlorethamine gel, marketed as Valchlor, for treating early-stage (I-IIA) mycosis fungoides, a form of cutaneous T-cell lymphoma. Operations centered on oncology therapeutics until acquisition by Actelion in 2013, following FDA rejection of the drug application the prior year. The company was previously known as Yaupon.
Ceptaris Therapeutics has 12 investors. Key investors include SVB, Actelion, HHS, Oxford Finance, and Burrill and Company.